Solotek Reports May 2026 Revenue of NT$716 Million, Up 36.7% Year-on-Year

Company Code: 6491 Company Name: Solotek Industry: Biotechnology and Healthcare Reporting Month: May 2026 Monthly Revenue: NT$716,194 thousand (NT$716 million) Year-on-Year Change: +36.7%

Keywords: Monthly Revenue, Biotechnology and Healthcare Industry

Solotek announced its financial performance for May 2026, reporting revenue of NT$716.194 million, a significant 36.7% increase compared to the same month last year. This growth reflects robust demand for the company's products and services, as well as its strengthened market position within the biotech and healthcare sector.

As a key player in the biotechnology and medical technology industry, Solotek specializes in the research, development, and commercialization of medical devices and health-tech solutions. The company has been expanding its market reach across Asia, particularly in Taiwan, mainland China, and Southeast Asia, driven by rising demand for high-quality healthcare innovations.

The revenue growth is attributed to successful product launches, expanded customer acquisition, and ongoing international expansion efforts. In addition to serving business clients (B2B), Solotek has also strengthened its presence in the consumer market (B2C), diversifying its revenue streams and enhancing brand visibility.

Looking ahead, Solotek expects continued strong performance in the second half of 2026. The company remains committed to investing in R&D and accelerating the commercialization of next-generation medical technologies, positioning itself for sustained long-term growth in the global healthcare market.